Koishihara Y - Search Results

1

Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24.

Ozaki S, Kosaka M, Wakatsuki S, Abe M, Koishihara Y, Matsumoto T. Ozaki S, et al. Among authors: koishihara y. Blood. 1997 Oct 15;90(8):3179-86. Blood. 1997. PMID: 9376601 Free article.

2

Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24.

Kawai S, Koishihara Y, Iida S, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H. Kawai S, et al. Among authors: koishihara y. Leuk Res. 2006 Aug;30(8):949-56. doi: 10.1016/j.leukres.2005.11.023. Epub 2006 Feb 13. Leuk Res. 2006. PMID: 16473407

3

Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models.

Kawai S, Yoshimura Y, Iida S, Kinoshita Y, Koishihara Y, Ozaki S, Matsumoto T, Kosaka M, Yamada-Okabe H. Kawai S, et al. Among authors: koishihara y. Oncol Rep. 2006 Feb;15(2):361-7. Oncol Rep. 2006. PMID: 16391855

4

Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells.

Ozaki S, Kosaka M, Wakahara Y, Ozaki Y, Tsuchiya M, Koishihara Y, Goto T, Matsumoto T. Ozaki S, et al. Among authors: koishihara y. Blood. 1999 Jun 1;93(11):3922-30. Blood. 1999. PMID: 10339501 Free article.

5

The humanized anti-HM1.24 antibody effectively kills multiple myeloma cells by human effector cell-mediated cytotoxicity.

Ono K, Ohtomo T, Yoshida K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Tsuchiya M. Ono K, et al. Among authors: koishihara y. Mol Immunol. 1999 Apr;36(6):387-95. doi: 10.1016/s0161-5890(99)00029-2. Mol Immunol. 1999. PMID: 10444002

6

Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.

Rew SB, Peggs K, Sanjuan I, Pizzey AR, Koishihara Y, Kawai S, Kosaka M, Ozaki S, Chain B, Yong KL. Rew SB, et al. Among authors: koishihara y. Clin Cancer Res. 2005 May 1;11(9):3377-84. doi: 10.1158/1078-0432.CCR-04-0650. Clin Cancer Res. 2005. PMID: 15867238

7

Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.

Ohtomo T, Sugamata Y, Ozaki Y, Ono K, Yoshimura Y, Kawai S, Koishihara Y, Ozaki S, Kosaka M, Hirano T, Tsuchiya M. Ohtomo T, et al. Among authors: koishihara y. Biochem Biophys Res Commun. 1999 May 19;258(3):583-91. doi: 10.1006/bbrc.1999.0683. Biochem Biophys Res Commun. 1999. PMID: 10329429

8

New xenograft model of multiple myeloma and efficacy of a humanized antibody against human interleukin-6 receptor.

Tsunenari T, Koishihara Y, Nakamura A, Moriya M, Ohkawa H, Goto H, Shimazaki C, Nakagawa M, Ohsugi Y, Kishimoto T, Akamatsu K. Tsunenari T, et al. Among authors: koishihara y. Blood. 1997 Sep 15;90(6):2437-44. Blood. 1997. PMID: 9310495 Free article.

9

Acquisition of growth autonomy and tumorigenicity by an interleukin 6-dependent human myeloma cell line transfected with interleukin 6 cDNA.

Okuno Y, Takahashi T, Suzuki A, Fukumoto M, Nakamura K, Fukui H, Koishihara Y, Ohsugi Y, Imura H. Okuno Y, et al. Among authors: koishihara y. Exp Hematol. 1992 May;20(4):395-400. Exp Hematol. 1992. PMID: 1568457

10

Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130.

Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, Yancopoulos GD, Taga T, Kishimoto T. Narazaki M, et al. Among authors: koishihara y. Blood. 1993 Aug 15;82(4):1120-6. Blood. 1993. PMID: 8353278 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters